Chromocell Therapeutics Corporation (CHRO) — Financial Flexibility Index
Chromocell Therapeutics Corporation (CHRO) has a Financial Flexibility Index of -0.06x as of June 2025. Free cash flow of $-447.14K (operating CF $-447.14K minus capex $0.00) represents 0% of total liabilities ($7.32 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Chromocell Therapeutics Corporation Financial Flexibility Index (2020–2024)
Historical Financial Flexibility Index trend for Chromocell Therapeutics Corporation across 9 annual periods. See Chromocell Therapeutics Corporation short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Chromocell Therapeutics Corporation (2020–2024)
Year-by-year free cash flow to debt coverage for Chromocell Therapeutics Corporation. For the full company profile including market capitalisation, see CHRO market cap overview.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.42x | $-5.79 Million | $-5.79 Million | $4.08 Million | ▼ -845.9% |
| 2023 | -0.15x | $-981.03K | $-981.03K | $6.54 Million | ▲ +0.0% |
| 2023 | -0.15x | $-981.03K | $-981.03K | $6.54 Million | ▲ +64.0% |
| 2022 | -0.42x | $-1.57 Million | $-1.57 Million | $3.76 Million | ▲ +0.0% |
| 2022 | -0.42x | $-1.57 Million | $-1.57 Million | $3.76 Million | ▲ +3.8% |
| 2021 | -0.43x | $-1.59 Million | $-1.59 Million | $3.68 Million | ▲ +0.0% |
| 2021 | -0.43x | $-1.59 Million | $-1.59 Million | $3.68 Million | ▲ +56.4% |
| 2020 | -0.99x | $-3.63 Million | $-3.63 Million | $3.65 Million | ▲ +0.0% |
| 2020 | -0.99x | $-3.63 Million | $-3.63 Million | $3.65 Million | — |